metaEvidence - overview

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - adjuvant 13

antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib
palbociclib plus endocrine therapy
HER inhibitor
HER2 inhibitor
neratinib based treatment
neratinib
pertuzumab based treatment
pertuzumab plus trastuzumab
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
mTOR inhibitors
everolimus
poly ADP-ribose polymerase (PARP) inhibitor
olaparib

versus all
vs chemotherapy
vs doxorubicin plus cyclophosphamide followed by docetaxel
vs endocrine therapy
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
vs trastuzumab
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

button bars forest bayes pooled summary circles


			iDFS
breast cancer - adjuvant breast cancer - adjuvant
versus placebo
	neratinib vs. placebo	1	-

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open